Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1971 Jun;42(2):242-53.
doi: 10.1111/j.1476-5381.1971.tb07105.x.

Pharmacological properties of centrally administered ouabain and their modification by other drugs

Pharmacological properties of centrally administered ouabain and their modification by other drugs

N S Doggett et al. Br J Pharmacol. 1971 Jun.

Abstract

1. Ouabain given by intracerebroventricular injection to mice in small doses (0.1-0.4 mug) produced a dose related depression of central nervous activity, characterized by a reduction in spontaneous locomotor activity, hypothermia, catalepsy and ptosis, lowered body posture and lack of response to external stimuli. Doses above 0.4 mug were excitatory, convulsant and lethal.2. The depressant effects could be antagonized by (+)-amphetamine, desmethylimipramine, dibutyryl cyclic 3'5'-adenosine monophosphate and caffeine.3. The MAO inhibitor nialamide produced only a small antagonism of ouabain, resulting in a greater rate of recovery from the depressant effects of ouabain.4. The depressant effects were associated with a marked elevation of whole-brain dopamine levels with little change in noradrenaline or 5-hydroxytryptamine.5. The dopamine-beta-hydroxylase inhibitor sodium diethyldithiocarbamate, administered by intracerebroventricular injection, produced effects qualitatively similar to those seen after ouabain.6. An interference with central transmitter function is postulated as a possible mode of action of intracerebroventricularly injected ouabain.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int J Neuropsychiatry. 1965 Aug;1(4):388-90 - PubMed
    1. J Pharm Pharmacol. 1966 Jan;18(1):60-2 - PubMed
    1. J Neurochem. 1967 Mar;14(3):283-90 - PubMed
    1. Ann N Y Acad Sci. 1967 Feb 10;139(3):849-59 - PubMed
    1. Life Sci. 1967 Aug 1;6(15):1653-63 - PubMed

MeSH terms

LinkOut - more resources